What are the opening hours?

Monday 9:15am - 6:15pm Tuesday 9:15am - 6:15pm Wednesday 9:15am - 6:15pm Thursday 9:15am - 6:15pm Friday 9:15am - 6:15pm

Sailifesciences

Home
India
Turkapalli
Sailifesciences

Sai Life Sciences works with innovator pharma and biotech companies to accelerate the discovery, development and manufacture of complex small molecules.

Our Vision is to support our global innovator partners bring 25 new medicines to life by 2025.

25/02/2026

Join experts from Sai Life Sciences Ltd, Agility Life Sciences, and Centrix Pharma Solutions to discover how an integrated CMC partnership can streamline development, reduce risk, and accelerate your path to the clinic.

Panel Members
• Dean Edney, Senior VP & Head – P R&D, Sai Life Sciences
• Claire Thompson, CEO, Agility Life Sciences
• Chris Davison, CEO, Centrix Pharma

Moderator
• Stephen Hermitage, Head of CMC Business Development, Sai Life Sciences

What will be the key areas of discussion?
• How integrated workflows shorten timelines
• Early CMC decisions that influence FIH readiness
• Strategies to reduce development risk & cost
• Real‑world insights from CMC and CRDMO experts

Register now: https://www.sailife.com/fasttofirstinhumanwebinar/
Seats are limited for this live session.

24/02/2026

Stories have the power to spark ambition!

Recently, four of our chemists from Sai Life Sciences Manchester, Kitty Bullard, Katie Smith, Emily Pocock, and Hannah Ashton took part in “Another Way: Inspiring Girls into STEM,” organised by ARC Mindset CIC to mark International Women in STEM Day. They shared their personal journeys into chemistry and offered a real-world view of what a career in industry looks like.

The event brought together 150 girls from Grades 9 and 10 across schools in Stockport and South Manchester, UK, with one shared goal: encouraging more young women to explore STEM careers.

20/02/2026

Sai Life Sciences will recruit 700+ scientific, technical, and management professionals in FY27 as we expand to meet rising global demand for integrated drug discovery, development, and manufacturing services.

From medicinal chemistry and biology to DMPK, process development, peptides, quality, manufacturing, business development, and program management — we’re strengthening capabilities across the value chain.

A specific area of focus through this recruitment drive will be on attracting high-calibre scientists from leading institutions in India and globally, reflecting the increasing complexity of programs being entrusted to Sai Life Sciences and the higher scientific expectations placed on Indian CRDMOs by global innovator companies.

Read the full announcement here: https://www.sailife.com/sai-life-sciences-to-recruit-700-professionals-in-fy27/

18/02/2026

The 2-day BioAsia 2026 brought together leaders from across the life sciences ecosystem for dialogue, collaboration, and forward-looking conversations.

Our MD & CEO, Krishna Kanumuri, joined industry leaders at the inaugural session, presided over by the Hon’ble Chief Minister of Telangana, A. Revanth Reddy. Later in the day, he participated in a panel discussion on “CRDMO 2.0: AI as a Force Multiplier Across the Value Chain,” where he underscored that the industry must continually reimagine itself to stay competitive in an AI-driven landscape. While AI presents transformative potential, he noted that meaningful impact can begin with the low-hanging opportunities — improving manufacturing efficiency, reducing timelines, ensuring accurate data, and increasing overall speed across projects.

Across both days, our booth witnessed strong engagement from industry stakeholders, collaborators, and young professionals. We were particularly encouraged by the steady influx of talent enquiries, reflecting growing interest in building careers with Sai Life Sciences and being part of a globally integrated CRDMO platform.

11/02/2026

We were pleased to host the UK’s Centre for Process Innovation (CPI) team at our Integrated R&D Center, Genome Valley, along with representatives from the BRIC - Centre for DNA Fingerprinting and Diagnostics (CDFD). The visit provided them an immersive view of our integrated discovery capabilities, spanning Medicinal Chemistry, Drug Metabolism and Pharmacokinetics (DMPK), and Biology, and demonstrated how we enable seamless Integrated Drug Discovery (IDD) through cross-functional scientific collaboration.

The visit is part of the ongoing UK–India collaboration efforts supported by the British High Commission, Hyderabad, focused on strengthening manufacturing and life sciences innovation partnerships.

06/02/2026

We have announced our financial results for the third quarter ended December 2025. Here are the key highlights:
▪️ Revenue from Operations stood at ₹556 Cr for Q3FY26 compared to ₹440 Cr in Q3FY25, an increase of 27% driven by strong growth both in CRO and CDMO services
▪️ EBITDA stood at ₹191 Cr for Q3FY26 compared to ₹124 Cr in Q3FY25, an increase of 54%
▪️ PAT stood at ₹100 Cr for Q3FY26 compared to ₹54 Cr in Q3FY25, an increase of 86%

For more details, read here: https://www.sailife.com/sai-life-sciences-limited-delivers-robust-performance-in-9mfy26/

29/01/2026

We've entered into a strategic collaboration with Mabtech, a global life science tools company specializing in advanced immunoassays, to establish our Boston laboratory as a co-marketed US ex*****on and demonstration hub for the Mabtech EYRA™ platform.

Under this collaboration, Sai and Mabtech will jointly deliver advanced immunology assay services — including high-sensitivity multiplex cytokine and phenotyping workflows — powered by the EYRA platform installed at Sai’s Boston discovery site. This initiative accelerates access to next-generation immune profiling capabilities for biopharma and biotech companies working in immuno-oncology, vaccines, inflammation, and cellular therapy.

Read full story here: https://www.sailife.com/mabtech-and-sai-life-sciences-announce-strategic-collaboration-to-advance-immunology-research-with-eyra-platform-at-sai-boston-site/

27/01/2026

Sai Life Sciences will be at BioAsia 2026 (Feb 17–18, Hyderabad), the premier life sciences and health-tech event hosted by the Government of Telangana, bringing together global leaders under the theme 'TechBio Unleashed: AI, Automation & the Biology Revolution.'

We are one of the fastest growing contract research, development, and manufacturing organization (CRDMO), working with innovator pharma and biotech companies to speed up the journey from discovery to commercialization.

With our roots in Hyderabad, we have grown alongside the city’s life sciences cluster—drawing strength from its skilled workforce and research ecosystem while actively helping build capabilities that serve the global industry. Come meet our team to explore how we can collaborate to advance the next generation of medicines.

01/01/2026

This New Year’s Day, we’re sharing an initiative that has been quietly taking shape over the past few weeks.

Story Hour’ is a weekly volunteering initiative where our Saimers read with children at government schools, fostering connection, curiosity, and a love for learning.

In partnership with Pustakaar, these sessions bring stories to life through read-alouds and simple activities that spark imagination, build language skills, and make reading joyful. It’s a small commitment of time—but one that opens up big worlds for young minds.

Story Hour is part of Sai Cares, our employee volunteering initiative that brings colleagues together to give back through time, care, and shared purpose.

Here’s to a year of learning, kindness, and stories that stay with us.

19/12/2025

We have released our Sustainability Report for 2024–25. Aligned with the Global Reporting Initiative (GRI) Universal Standards 2021 and the Sustainability Accounting Standards Board (SASB) standards, this sixth edition is presented under the theme “Driving climate action, deepening stakeholder trust.”

During the year, we advanced our internally defined Sustainable Development Goals (SDGs), outlining a clear roadmap to meet our sustainability commitments by March 31, 2027. The report highlights progress in greenhouse gas reduction, a significant increase in renewable energy usage—with 96% of our API manufacturing unit in Bidar powered by renewables—and reductions in specific water consumption across facilities.

Read the Sustainability Report here: https://www.sailife.com/sustainability-report/2025/

18/12/2025

One year ago, a bell rang.

On December 18, 2024, we marked the beginning of a new chapter for Sai Life Sciences as a listed company.

Our arrival on the public stage has coincided with a significant period of churn and change in the global pharmaceutical ecosystem. Innovation cycles have accelerated. New modalities are taking center stage. Supply chains continue to recalibrate. Across the industry, the focus has sharpened on ex*****on, resilience, and long-term partnerships—particularly across CRO and CDMO models that enable scale, speed, and scientific depth.

Against this backdrop, the year for us has been about quiet ex*****on—strengthening the foundations needed to support complex science at scale. We have expanded our scientific teams, increased operating scale across our laboratories and plant, and deepened capabilities aligned to the evolving needs of global pharma and biotech partners.

What has remained constant is the culture we carried into listing: deep scientific commitment, disciplined client-centric ex*****on, and a clear focus on long-term value creation.

As we look ahead, we carry this momentum forward, with the same ownership, purpose, and pride that have defined our journey so far.

11/12/2025

Sai Life Sciences, along with its client Bayer, has published a case study in The Climate Drive, an open digital platform powered by the WBCSD – World Business Council for Sustainable Development that helps businesses learn and take action on their Net Zero pathways.

The case study highlights how Sai Life Sciences implemented a hybrid solar–wind power model at its flagship manufacturing site in Bidar, India, under a long-term captive power purchase agreement (PPA). Driven by a commitment to responsible operations and to advancing the sustainability goals of the programs we support, this transition increased the site’s renewable energy usage from 0% to 96% in just three years. It significantly led to reduction of Scope 2 emissions and creating a scalable model for responsible energy adoption.

You can read the full case study here: https://www.theclimatedrive.org/action-library/shift-to-renewables-from-0-to-96-in-3-years

As part of Bayer’s broader engagement on climate action, Sai Life Sciences was also recognized in the Igniting Networks Decarbonization Excellence Award 2025, reflecting the measurable progress captured in this initiative.

Address

DS-7, IKP Knowledge Park, Turkapally Village, Shameerpet Mandal, Medchal-Malkajgiri District
Turkapalli
500078

Opening Hours

Monday	9:15am - 6:15pm
Tuesday	9:15am - 6:15pm
Wednesday	9:15am - 6:15pm
Thursday	9:15am - 6:15pm
Friday	9:15am - 6:15pm

Website

https://www.sailife.com/

Alerts

Be the first to know and let us send you an email when Sailifesciences posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to Sailifesciences:

Want your practice to be the top-listed Clinic in Turkapalli?